Baumeister Susanne H C, Mohan Gopi S, Elhaddad Alaa, Lehmann Leslie
Boston Children's Hospital, Division of Pediatric Hematology-Oncology, Boston, MA, United States.
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
Front Oncol. 2022 Mar 24;12:841117. doi: 10.3389/fonc.2022.841117. eCollection 2022.
Immune effector cells (IEC) are a powerful and increasingly targeted tool, particularly for the control and eradication of malignant diseases. However, the infusion, expansion, and persistence of autologous or allogeneic IEC or engagement of endogenous immune cells can be associated with significant systemic multi-organ toxicities. Here we review the signs and symptoms, grading and pathophysiology of immune-related toxicities arising in the context of pediatric immunotherapies and haploidentical T cell replete Hematopoietic Cell Transplantation (HCT). Principles of management are discussed with particular focus on the intersection of these toxicities with the requirement for pediatric critical care level support.
免疫效应细胞(IEC)是一种强大且靶向性日益增强的工具,尤其适用于控制和根除恶性疾病。然而,自体或异体免疫效应细胞的输注、扩增和留存,或内源性免疫细胞的激活,可能会引发显著的全身性多器官毒性。在此,我们综述了儿科免疫疗法和单倍体相合、富含T细胞的造血细胞移植(HCT)背景下出现的免疫相关毒性的体征和症状、分级及病理生理学。我们还讨论了管理原则,特别关注这些毒性与儿科重症监护支持需求的交叉点。